This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2 (I)

T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-f.sub.3-T.sub.4 (II), as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:
T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)
T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-f.sub.3-T.sub.4(II),
as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:
T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)
T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-f.sub.3-T.sub.4(II),
as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-C.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)

T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-f.sub.3-T.sub.4(II),

as described in the present application. Methods of using these macrostructures are also disclosed.

This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II:

T.sub.1-f.sub.0-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-C.sub.2-d.sub.2-e.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-e.sub.3-T.sub.2(I)

T.sub.3-g.sub.0-a.sub.1-b.sub.1-c.sub.1-d.sub.1-e.sub.1-f.sub.1-g.sub.1-a.sub.2-b.sub.2-c.sub.2-d.sub.2-f.sub.2-g.sub.2-a.sub.3-b.sub.3-c.sub.3-d.sub.3-f.sub.3-T.sub.4(II),

as described in the present application. Methods of using these macrostructures are also disclosed.

In an example, a method of butadiene sequestration includes receiving an input stream that includes butadiene. The method includes directing the input stream to a first sulfur dioxide charged zeolite bed for butadiene sequestration via a first chemical reaction of butadiene and sulfur dioxide to form sulfolene.

The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38 MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38 MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.

The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.